Skip to Content

EHA 2025 I The European Hematology Association

EHA 2025

EHA 2025: Improved Outcomes in High-Risk MCL with Acalabrutinib Combination Therapy

juni 2025 / Jan Andreasen

Malin Rasmussen

EHA 2025: Radiotherapy in FL Linked to Low Relapse Rates

juni 2025 / Malin Rasmussen

EHA25 Lymfom

Frida Bugge Askeland

EHA 2025: Impact of Treating MRD Relapse Post 1L in Multiple Myeloma

juni 2025 / Frida Bugge Askeland

EHA25 Myelomatose

EHA 2025: Novel Immune Escape Pathway in AML Identified and Successfully Blocked

juni 2025 / Hæmatologi / Carl Sandén

EHA 2025: Tripled Cardiac Morbidity Risk After Hodgkin Lymphoma Therapy

juni 2025 / Hæmatologi / Sara Rossetti

EHA 2025: Overcoming Venetoclax Resistance

juni 2025 / Hæmatologi / Justinas Daraskevicius

EHA 2025: First-in-Class BTK Degrader Drives Strong Responses in R/R CLL/SLL

juni 2025 / Hæmatologi / Lydia Scarfò

Abstracts fra EHA 2022

Ibrutinib keeps on delivering now as first-line treatment for older patients with mantle cell lymphoma

juni 2022 / Hæmatologi / BestPractice Nordic

Superior safety profile for decitabine vs chemotherapy for older patient with AML

juni 2022 / Hæmatologi / BestPractice Nordic

A novel CAR-T cell therapy thas proven highly effective for patients with RRMM

juni 2022 / Hæmatologi / BestPractice Nordic

A new phase 3 trial shows significantly prolonged overall survival for patients with AML

juni 2022 / Hæmatologi / BestPractice Nordic

Improved PFS is achievable using targeted therapy combinations with venetoclax in fit patients with treatment naïve CLL

juni 2022 / Hæmatologi / BestPractice Nordic

Treatment of Burkitt lymphoma with DA-EPOCH-R is associated with significant less infectious complications, transfusions, and hospitalization days

juni 2022 / BestPractice Nordic

Gå ikke glip af det nyeste fra Hæmatologi

Skriv dig på og få nye artikler, MEDtalks og magasiner i din indbakke

Send mig seneste nyt fra hæmatologi

Back to top